8:45–9:45 a.m.

Organ Preservation: Past, Present and Future, James Anderson, ST

Organ preservation has advanced considerably, but continued research is necessary to improve the success of transplantation. During this session, organ-preservation solutions, techniques and device usage will be discussed.

Learning Objectives:

1. Review the history of organ preservation at UW Health and nationally.
2. Describe advancements in organ-preservation methods and techniques.
3. Discuss the research and future trends in organ preservation.

10:00–11:15 a.m.

Updates in Lung Transplantation, Richard Cornwell, MD; Nilto De Oliveira, MD; and Linda Dawson, Lung Recipient

Lung transplantation is an accepted modality of treatment for advanced-stage lung disease. This presentation will focus on indications and outcomes for lung transplantation.

Learning Objectives:

1. Outline advanced-lung-disease therapies and indications for lung transplantation.
2. Discuss the criteria for appropriate referral of potential lung transplant candidates to a lung transplant center.
3. Review the recently updated International Society for Heart and Lung Transplantation guidelines with a focus on general indications and contraindications, as well as disease-specific guidelines.
4. Summarize outcomes and current trends in lung transplantation.

11:15 a.m.–12:30 p.m.

Alpha/Beta Depletion in Haploidentical Donors to Reduce Graft-Versus-Host Disease, Vaishalee Kenkre, MD, and Walter Longo, MD

Haploidentical stem cell transplantation is a valid approach for patients at high risk of disease progression without human-leukocyte-antigen- (HLA)-matched donors. This session will summarize background literature in the field of manipulating peripheral blood stem cell (PBSC) products from related donors who match at least five out of 10 of HLAs with the intended recipient. There will also be a discussion on an exciting new clinical trial at UW utilizing this technology to treat patients with relapsed/refractory lymphomas with allogeneic PBSC transplant, with the goals of preserving engraftment, reducing the risk for graft-vs.-host disease and maximizing the graft-vs.-lymphoma effect.

Learning Objectives:

1. State the purpose of alpha/beta depletion in haploidentical donors.
2. List at least one advantage to using a haploidentical family member as a donor.
3. Describe how this trial makes allogeneic transplant available to a group of patients previously considered ineligible for transplant.

1:30–2:30 p.m.

End-Stage Heart Failure: Drugs, Devices or a New Heart? Lucian Lozonschi, MD, and Ravi Dhingra, MD, MPH

Despite advances in pharmacologic and nonpharmacologic therapies, the number of people affected by heart failure continues to grow. During this presentation, current innovations for improving heart-failure-patient and transplant-patient care will be addressed.

Learning Objectives:

1. List all available advanced-heart-failure therapies, optimization of heart-failure medications, and indications for left ventricular assist devices (LVADs) and/or cardiac transplant.
2. Recognize eligibility, indications and contraindications for listing a severely advanced-heart-failure patient on the heart-transplant waiting list.
3. Discuss destination therapy LVAD support and its role in the treatment of advanced heart failure.
4. Compare outcomes between LVADs and heart transplantation.

2:45–3:45 p.m.

A Case from the Heart, Lucian Lozonschi, MD; Maryl Johnson, MD, FACC; Veronica Lawrence, RN, BSN, CPTC, UW Organ and Tissue Donation; Walt Goodman, Heart Recipient; and Meredith Mackaman, Donor Mom

This case presentation will include participation from the transplant team, the procurement team, a donor family and a transplant recipient.

Learning Objectives:

1. Describe the interconnectedness of the organ donation and transplant processes.
2. State the contribution each team member makes to the donation-and-transplantation process.
3. Discuss the amazing gift of life made possible through organ donation and transplantation.

3:45–4:45 p.m.

Donation after Circulatory Death (DCD): Effective Organ Procurement Organization and Transplant Program Relationship, Tony D'Alessandro, MD

The main factor limiting organ donation is the availability of suitable donors and organs. DCD has made an impact on the widening gap between demand for and supply of donor organs. This presentation will focus on DCD success at UW and nationally, as well as trends for its future use.

Learning Objectives:

1. Discuss the history of DCD.
2. Outline current trends and practices in DCD donation.
3. State the importance of the transplant program and organ procurement organization’s relationship in having a successful DCD program.
4. Review future trends in DCD.